Michael Andersson

机构：University of Copenhagen, Copenhagen University Hospital, Rigshospitalet · ORCID：0000-0003-4440-4800

发表论文 165 篇 · 总被引 17179 次 · h-index 46

代表论文

• Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up (2021 · Journal of Clinical Oncology · 被引 374)
• Checkpoint inhibitors in breast cancer – Current status (2017 · Cancer Treatment Reviews · 被引 159)
• The effects of individually tailored nurse navigation for patients with newly diagnosed breast cancer: a randomized pilot study (2017 · Acta Oncologica · 被引 71)
• Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for EarlyTOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial (2017 · Journal of Clinical Oncology · 被引 68)
• Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism—A systematic review (2018 · Cancer Medicine · 被引 41)
• Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update (2024 · Journal of Clinical Oncology · 被引 37)